The Global Active Pharmaceutical Ingredient Market Is Expected to Reach USD 205.51 Billion by 2020

01 Dec, 2015, 06:10 ET from Research and Markets

DUBLIN, Dec. 1, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/7fxqq4/active) has announced the addition of the "Active Pharmaceutical Ingredient Market - Global Forecast to 2020" report to their offering.


The active pharmaceutical ingredient market by type is categorized into innovative API and generic API. The innovative APIs segment accounted for highest share of the total API market in 2015. Patent protection of innovative APIs and higher prices compared to their generic equivalent are major factors driving the market growth for this segment.

The active pharmaceutical ingredient market, by type of manufacturer, is segmented into captive and merchant manufacturers. The captive manufacturers segment accounted for major share of the total API market. The API market is expected to be dominated by captive manufacturers in 2015; however, it is slowly losing its share to contract manufacturers, owing to the complexity and high expenses associated with in-house manufacturing of API as well as the increased competition from emerging contract manufacturers.

The merchant manufacturing segment is segmented into innovative merchant API and generic merchant API. The innovative merchant APIs market is estimated to account for the major share of larger share in 2015; however, the growth of this market is expected to slow down due to imminent patent cliff, increasing cost of innovative drugs, and significant growth opportunities for generic merchant APIs market in emerging markets of India, China, and Latin America that offer low-cost manufacturing.

The market for generic merchant API is expected to witness higher growth attributed to increasing healthcare costs, government emphasis on generics for reducing healthcare costs, and decreasing pipelines of global pharmaceutical products.

The active pharmaceutical ingredient market, by method of synthesis, is segmented into synthetic APIs and biotech APIs. The synthetic APIs market is estimated to account for the higher share; however, this share is expected to decline owing to rapid advances in the biopharmaceuticals market. The synthetic APIs market is subsegmented into innovative synthetic APIs and generic synthetic API.

Biotech API are estimated segment accounts for smaller share of the market as the use of biotechnology in pharmaceutical industry is a relatively new concept, and is still in the infancy state. However, it is expected to show high growth owing to the boom in biotechnology industry worldwide and advances in manufacturing and processing techniques of biopharmaceuticals coupled with increasing demand for the treatment of cancer and diabetes.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Active Pharmaceutical Ingredients Market, By Synthesis

7 Active Pharmaceutical Ingredients Market, By Type Of Manufacturer

8 Active Pharmaceutical Ingredients Market, By Type

9 Active Pharmaceutical Ingredients Market, By Therapeutic Area

10 High-Potency Active Pharmaceutical Ingredients Market

11 Active Pharmaceutical Ingredients Market, By Region

12 Competitive Landscape

13 Company Profiles

  • Albemarle Corporation
  • Allergan Plc
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim
  • Dr. Reddy'S Laboratories Ltd.
  • Mylan Inc.
  • Novartis International Ag
  • Sigma-Aldrich Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited

For more information visit http://www.researchandmarkets.com/research/7fxqq4/active

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com